Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Abdel Wahab, Noha ^a,b   Shah, Mohsin ^a   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CELL CYCLE CHECKPOINT; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 85013634537     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160221     Document Type: Review

References (38)

1. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013; 1:12. doi: 10.1186/2051-1426-1-12 PMID: 24829749
2. Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant. 2014; 14(9):1985–91. doi: 10.1111/ajt.12834 PMID: 25098238
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4):252–64. doi: 10.1038/nrc3239 PMID: 22437870
4. Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015; 45(7):1892–905. doi: 10.1002/eji.201344413 PMID: 26018646
5. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014; 65:185–202. doi: 10.1146/annurev-med-092012-112807 PMID: 24188664
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711–23. doi: 10.1056/ NEJMoa1003466 PMID: 20525992
7. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert review of anticancer therapy. 2015; 15(9):981–93. doi: 10.1586/14737140.2015.1074862 PMID: 26313415
8. Ai M, Curran MA. Immune checkpoint combinations from mouse to man. Cancer immunology, immunotherapy: CII. 2015; 64(7):885–92. doi: 10.1007/s00262-014-1650-8 PMID: 25555570
9. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC medicine. 2015; 13:211. doi: 10.1186/s12916-015-0455-8 PMID: 26337719
10. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015; 26(9:1824–1829). doi: 10.1093/annonc/mdv182 PMID: 25888611
11. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015; 34(43:5411–7). doi: 10.1038/onc.2015.5 PMID: 25659583
12. Horvat TZ, Adel NG, Dang TO, Woo K, Panageas K, Momtaz P, et al. Immune related adverse events (irAEs) and overall survival (OS) in patients (pts) with melanoma (mel) treated outside of a clinical trial with ipilimumab (ipi) at memorial sloan kettering (MSK). Pigment Cell and Melanoma Research. 2014;27; 1169:1200.
13. Johnson DB, Friedman DL, Berry EG, Decker I, Ye F, Zhao S, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015.
14. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE. 2013; 8(1):e53745. doi: 10.1371/journal.pone.0053745 PMID: 23341990
15. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology. 2015; 33(18):2092–9. doi: 10.1200/JCO.2014.60.0379 PMID: 25918278
16. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21):2691–7. doi: 10.1200/JCO.2012.41.6750 PMID: 22614989
17. Chan MMK, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. Journal of Immunotherapy. 2015; 38 (1):37–9. doi: 10.1097/CJI.0000000000000060 PMID: 25415286
18. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009; 361(2):211–2.
19. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis rheumatol. 2014; 66(3):768–9. doi: 10.1002/art.38282 PMID: 24574239
20. Hanrahan P, Van Der Westhuizen A, Collins S, Owens D, Hersey P. Delayed autoimmune effects in patients treated with antibodies against the checkpoint inhibitor PD1. JDDG—Journal of the German Society of Dermatology. 2013; 11:16.
21. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009; 36(4):518–20. PMID: 19650371
22. Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015; 151(2):195–9. doi: 10.1001/ jamadermatol.2014.2233 PMID: 25321335
23. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. Drug safety. 2007; 30(5):367–73. PMID: 17472416
24. IBM Corp. Released 2012. IBM SPSS Statistics for Windows VA NIC.
25. Ledezma B, Binder S, Hamid O. Atypical clinical response patterns to ipilimumab. Clin J Oncol Nurs. 2011; 15(4):393–403. doi: 10.1188/11.CJON.393-403 PMID: 21810572
26. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015; 373(3):288–90. doi: 10.1056/NEJMc1505197 PMID: 26176400
27. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134–44. doi: 10.1056/ NEJMoa1305133 PMID: 23724846
28. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal of Clinical Oncology. 2013; 31(15: suppl 9010).
29. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974–82. doi: 10.1200/JCO.2014.59.4358 PMID: 25605845
30. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443–54. doi: 10. 1056/NEJMoa1200690 PMID: 22658127
31. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology. 2014; 32(10):1020–30. doi: 10.1200/JCO.2013.53.0105 PMID: 24590637
32. Dadu R, Zobniw C, Diab A. Managing Adverse Events With Immune Checkpoint Agents. Cancer journal. 2016; 22(2):121–9.
33. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139–48. doi: 10.1016/j.ejca.2015.11.016 PMID: 26765102
34. Horvat TZ, Adel NG, Dang TO, Woo K, Panageas K, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. Journal of Clinical Oncology. 2015; 33(28):3193–8. doi: 10.1200/JCO.2015.60.8448 PMID: 26282644
35. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology. 2011; 29(15: supp 1).
36. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006; 18(2):206–13. PMID: 16464564
37. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010; 25(6):601–13. doi: 10.1089/cbr.2010.0865 PMID: 21204754
38. Tomasello G, Tralongo P, Amoroso F, Damiani P, Sinagra E, Noto M, et al. Dysmicrobism, Inflammatory Bowel Disease and Thyroiditis: Analysis of the Literature. Journal of biological regulators and homeostatic agents. 2015; 29(2):265–72. PMID: 26122213